Covid-19 roundup: No­var­tis treat­ment comes up short in PhI­II; Hu­mani­gen ex­pands tri­al, but draws crit­i­cism

A ma­jor play­er try­ing to adapt an an­ti-in­flam­ma­to­ry for Covid-19 has seen the drug fall flat.

No­var­tis re­port­ed Fri­day that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.